Eli Lilly investing $27B more in US manufacturing
Eli Lilly is doubling its U.S. manufacturing investment since 2020 as it seeks to produce more drugs domestically. Its latest investment is to the tune of $27 billion.
Zepbound maker Eli Lilly announces $27 billion investment in US drug manufacturing as Trump threatens tariffs
Eli Lilly, the maker of blockbuster weight loss and diabetes drugs Zepbound and Mounjaro, said it will invest an additional $27 billion to build four new manufacturing plants in the United States, shoring up domestic manufacturing as President Donald Trump threatens new tariffs on pharmaceuticals.
Eli Lilly plans at least $27 billion in new U.S. manufacturing investments
Eli Lilly said it will invest at least $27 billion to build four new manufacturing sites in the U.S. as demand for its weight loss and diabetes injections soars and the company develops new drugs. The move comes as companies work to build goodwill with President Donald Trump,
Lilly Puts $27B Into U.S. Manufacturing Bump Following Trump’s Tariff Threats
The move comes after President Donald Trump warned Big Pharma leaders that he would impose tariffs on them if they refuse to reshore their manufacturing operations.
Lilly plans to invest $27 billion in new US plants as Trump threatens pharmaceutical tariffs
Eli Lilly plans to spend at least $27 billion to build four new manufacturing plants in the U.S., the drugmaker said at a Washington press conference on Wednesday, as it grapples with the threat of drug import duties from the Trump administration.
Eli Lilly expands US manufacturing build-out with $50B target
The company is doubling plans for capital spending on U.S. factories as President Donald Trump pressures the pharma industry to reshore drug production.
Eli Lilly plans to invest $27B to build four new US plants as tariffs loom
Pharmaceutical giant expects the move will create 3,000 high-skilled jobs and provide work for approximately 10,000 construction workers.
Eli Lilly unveils $27bn US investment as corporate America seeks to woo Trump
Eli Lilly has unveiled a $27 billion (€25.7 billion) investment in US manufacturing facilities as the pharmaceutical industry prepares for the threat of tariffs and mounts a charm offensive aimed at president Donald Trump’s new administration.
Eli Lilly To Invest $27B Building 4 New U.S. Manufacturing Sites
Eli Lilly and Co. plans to bolster its domestic medicine production with a $27B investment in four new U.S. pharmaceutical manufacturing sites, bringing its total capital commitment to future expansion to more than $50B.
Eli Lilly to spend $27 billion to expand U.S. manufacturing with four new sites
Eli Lilly & Co.’s stock rose 1.6% Wednesday, after the drug company announced plans to expand its U.S. manufacturing sites by adding four more locations this year, along with 13,000 high-wage jobs.
Eli Lilly Plans to Spend $27 Billion on Four New U.S. Plants
U.S. Secretary of Commerce Howard Lutnick said Lilly was doing "exactly what the President was hoping would happen."
Eli Lilly wants to make drugs in America. First it wants a tax cut
Eli Lilly (LLY), the maker of the blockbuster weight-loss drug Zepbound, announced Wednesday that it plans to invest $27 ...
FierceBiotech21h
As Trump targets DEI practices, 4 pharmas reaffirm commitment to diversifying clinical trials
Even as President Donald Trump wages a very public fight against diversity, equity and inclusion (DEI) initiatives in the ...